Status:
RECRUITING
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
Lead Sponsor:
Huashan Hospital
Conditions:
Kidney Cancer
Lymphomas
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of this study was to establish and optimize the \[18F\]RCCB6 and \[68Ga\]Ga-NOTA-RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis ...
Eligibility Criteria
Inclusion
- Be between 18 and 65 years of age and of either sex.
- Affected with renal cancer or lymphoma confirmed by puncture or surgical pathology.
- Informed consent must be signed in writing by the subject or his/her legal guardian or caregiver.
- Willingness and ability to cooperate with all programs of this study.
Exclusion
- Subjects meeting any of the following criteria will be excluded from the study:
- Severe hepatic and renal insufficiency;
- Targeted therapy prior to radiotherapy or PET/CT scan. Renal function: serum creatinine less than or equal to the upper limit of the normal range;
- Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
- History of serious surgery in the last month.
- Those who have participated in other clinical trials during the same period.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06148220
Start Date
October 1 2023
End Date
September 1 2024
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huashan Hospital
Shanghai, China, 200040